Orthocell Ltd

📌 Investor Event Orthocell Ltd (ASX: OCC) CEO and MD, Paul Anderson will be presenting at the HealthInvest summit in Sydney on Wednesday 2 April 2025, alongside leading Australian health and life sciences companies. Register now: https://lnkd.in/gSu2xbd9 $OCC #OCC #HealthInvest #Orthocell

𝐈𝐅𝐒𝐒𝐇 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐅𝐨𝐫𝐮𝐦 | 𝐖𝐞𝐝𝐧𝐞𝐬𝐝𝐚𝐲 𝟐𝟔 𝐌𝐚𝐫𝐜𝐡 𝟐𝟎𝟐𝟓 #Orthocell will be hosting an Industry Forum titled "Redefining Nerve Repair with Remplir™, an innovative resorbable collagen device" at the upcoming IFSSH & IFSHT Triennial Congress in Washington, D.C this month. Our distinguished faculty of experts will present on the attributes of our innovative collagen material which resembles epineurial structure in nerve repair. They will discuss current challenges with biomaterials and introduce a new clinical solution delivering consistent and predictable outcomes in nerve repair surgery. 🔹  Moderator: Dr Sonu Jain (US) 🔹  Prof Minghao Zheng (AU) 🔹  Dr Alex O'Beirne (AU) 🔹   Dr Tanya Burgess (AU) This session is particularly relevant for surgeons with an interest in translational science and advances in nerve repair surgery. The session will conclude with a Q&A panel discussion. For more information 👉 https://lnkd.in/giUtHUsd Or visit the Orthocell team at IFSSH 2025 at Booth #500. $OCC #Orthocell #innovation #regenerativemedicine #nervrepair #IFSSH2025 #IndustryForum #Remplir

Patient Milestone ✨ At the age of 17, Liam Shepherd's life changed forever when a horrific car accident left him with a C6 spinal cord injury and confinement to a wheelchair. Today, we're celebrating his move to independent living! The SOLD sign is up on his new house, marking an incredible, long-term goal for this determined and capable young man. Following a tough start to his recovery, Liam was offered the chance to participate in the Remplir™ clinical trial, undergoing nerve transfer therapy with leading surgeon Dr Alex O'Beirne and dedicated rehabilitation with OT Jaslyn Cullen. Since his surgery, Liam has reclaimed abilities he once thought impossible – including driving a modified car. At Orthocell, these are the stories that fuel our mission. Liam's journey from hospital bed to homeowner reminds us that with the right treatment, support and mindset, new chapters can begin – even after life-changing injuries. Congratulations on your new home, Liam. Your journey continues to inspire us all. $OCC #Orthocell #spinalcordinjury #nerverepair #innovation #Remplir Photo: Courtesy of Liam Shepherd. 

📆 2025 IFSSH and IFSHT Triennial Congress | 24-28 March #Orthocell is pleased to announce our participation at the 2025 IFSSH and IFSHT Triennial Congress from 24-28 March in Washington DC. Join our US Team at Booth #500 where we will be showcasing Remplir™, our innovative nerve repair solution designed to address the clinical challenges of peripheral nerve injuries. Remplir features a unique resorbable collagen structure that mimics epineural architecture, providing surgeons with a reliable platform for consistent and predictable nerve regeneration outcomes. This prestigious congress, hosted by the American Society for Surgery of the Hand, American Society of Hand Therapists, and American Association for Hand Surgery, offers an excellent opportunity to connect with leading specialists and discuss advances in peripheral nerve repair techniques. We look forward to engaging with the surgical community and sharing the clinical evidence supporting our technology's efficacy in facilitating optimal nerve repair. 📍 Visit Booth #500 to learn more about this revolutionary approach to peripheral nerve injuries. $OCC #innovation #regenerativemedicine #nervrepair #IFSSH2025 #IndustryForum #Remplir

🇸🇬 Singapore Regulatory Approval for Striate+™ Orthocell has received regulatory approval from Singapore's Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product, Striate+™. This approval complements existing approvals in the US, Europe/UK, Australia, New Zealand and Canada, and paves the way for further expansion into other ASEAN markets. BioHorizons, our global marketing and distribution partner, is already well established in Singapore, which will facilitate a fast transition to first sales in this key market. Orthocell CEO and MD, Paul Anderson, said: “We are delighted to receive Singaporean regulatory approval for Striate+ in this important regional gateway market. This approval provides additional validation of Orthocell’s high-quality products, manufacturing processes, and quality systems. Moreover, it enhances our ability to drive revenue growth as our distribution partner expands into global markets.” Read the ASX Release: https://lnkd.in/g-aMrJeK $OCC #Orthocell #Striate+ #dental #regenerativemedicine #global

📺 VIDEO REPLAY #Orthocell CEO and MD, Paul Anderson, hosted a webinar this morning to provide an important update on Orthocell's clinical and commercial plans. For those who were unable to attend or would like to review the information presented, a recording of the webinar is now available online. Watch the replay 👉 https://lnkd.in/gFQBPtz9 $OCC #Orthocell #innovation #nerverepair #regenerativemedicine #global

💻 Investor Webinar Orthocell CEO & MD, Paul Anderson, will deliver a comprehensive update to investors on the Company's global commercialisation push at 11am AEST on Wednesday 26 February. Participants must register to attend. Register to attend 👉 https://lnkd.in/gD2KUJu7 $OCC #Orthocell #innovation #nerverepair #regenerativemedicine #global

🇹🇭 𝐓𝐡𝐚𝐢𝐥𝐚𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 Orthocell Ltd has submitted a regulatory application to the FDA of Thailand to commence sales of our groundbreaking nerve repair device Remplir™, with clearance expected in Q3 CY2025. Remplir™ is now gaining record sales traction in Australia, New Zealand and Singapore, with all sights set on US FDA clearance in March/April 2025. Read the ASX Release 👉 https://lnkd.in/gUd2-7Xq $OCC #Orthocell #Remplir #nerverepair #regenerativemedicine #global

⚕️ 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐚𝐭 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐀𝐎𝐀 𝐕𝐢𝐜𝐭𝐨𝐫𝐢𝐚𝐧 𝐁𝐫𝐚𝐧𝐜𝐡 𝐀𝐒𝐌 | 𝟐𝟏-𝟐𝟑 𝐅𝐞𝐛𝐫𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟓 We're thrilled to be attending the 2025 AOA Victorian Branch ASM in Lorne this week, where our team will be showcasing our advanced regenerative medicine technologies. If you're visiting the conference, stop by our stand to meet the Orthocell team and learn more about our innovative cellular therapies and unique collagen medical device platform. Discover how our cutting-edge solutions can enhance your practice in regenerative medicine. Unable to attend? We'd still love to connect. Visit www.orthocell.com to learn more about our transformative technologies. $OCC #regenerativemedicine #cellulartherapies #conference #healthcare #Orthocell

🇨🇦 Canada submission update Orthocell Ltd has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its leading nerve repair product Remplir™ into the US$75 million Canadian nerve repair market. Health Canada is the regulatory authority responsible for regulating the importation, manufacture, export, and supply of medical devices. Evaluation of Orthocell’s application is now in progress with clearance expected in the second half of 2025. Read the ASX Release 👉 https://lnkd.in/gV6umKdD $OCC #Orthocell #Remplir #nerverepair #regenerativemedicine #global